Therapy of macular edema with an intravitreal dexamethasone implant;Klinischer einsatz eines intravitrealen dexamethason-implantats in der behandlung des makulaödems

Spektrum der Augenheilkunde

Volumn 20, Issue 5, 2006, Pages 231-233

  Georgopoulos, Michael ^a   Sacu, S ^a   Vecsei, P V ^a   Michels, S ^a   Kiss, C ^a   Scholda, C ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Intravitreal implant; Macular edema; Posurdex

Indexed keywords

DEXAMETHASONE; POLYMER; POSURDEX;

ARTICLE; BIODEGRADABILITY; CATARACT EXTRACTION; CILIARY DISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG TOLERANCE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; SIDE EFFECT; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 33845311186     PISSN: 09304282     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03163806     Document Type: Article

References (23)

1. Ciulla TA, Walker JD, Fong DS, Criswell MH (2004) Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 15 (3): 211-220
2. Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20: 244-250
3. Gualino V, Audren F, Erginay A, Haouchine B, Bergmann J, Gaudric A, Massin PG (2005) Intraocular pressure after intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Invest Ophthalmol Vis Sci E-Abstract 1433/B 202
4. Mason AR, Husain S, Tkatchenko AV, Fant J, Crosson CE (2005) Dexamethasone-induced upregulation of mitogen-activated protein kinase phophatase-1 (MKP-1) in the human trabecular meshwork cells. Invest Ophthalmol Vis Sci E-Abstract 3689/B 47
5. Jaffe GJ, Pearson PA, Ashton P (2000) Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina 20 (4): 402-3
6. Kimura H, Ogura Y (2001) Biodegradable polymers for ocular drug delivery. Ophthalmologica 215 (3): 143-55
7. Lee SB, Geroski DH, Prausnitz MR, Edelhauser HF (2004) Drug delivery through the sciera: effects of thickness, hydration, and sustained release systems. Exp Eye Res 78 (3): 599-607
8. Bodor N (1994) Designing safer ophthalmic drugs by soft drug approaches. J Ocul Pharmacol 10 (1): 3-15
9. Fialho SL, da Silva Cunha A (2005) Manufacturing techniques of biodegradable implants intended for intraocular application. Drug Deliv 12 (2): 109-16
10. Hilgers C, Klee D, Kompa S, Schrage N, Kirchhof B (2005) Evaluation of corticosteroid-loaded silicone microspheres for controlled intraocular drug delivery. Invest Ophthalmol Vis Sci E-Abstract 495/ B 469
11. Cheng CK, Berger AS, Pearson PA, Ashton P, Jaffe GJ (1995) Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci 36 (2): 442-53
12. Kodama M, Numaga J, Yoshida A, Kaburaki T, Oshika T, Fujino Y, Wu GS, Rao NA, Kawashima H (2003) Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models. Graefes Arch Clin Exp Ophthalmol 241 (11): 927-33
13. Tan DT, Chee SP, Lim L, Lim AS (1999) Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 106 (2): 223-31
14. Tan DT, Chee SP, Lim L, Theng J, Van Ede M (2001) Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology 108 (12): 2172-81
15. Wadood AC, Armbrecht AM, Aspinall PA, Dhillon B (2004) Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification. J Cataract Refract Surg 30 (4): 761-8
16. Lee SY, Chee SP, Balakrishnan V, Farzavandi S, Tan DT (2003) Surodex in paediatric cataract surgery. Br J Ophthalmol 87 (11): 1424-6 (Letter)
17. Kagaya F, Usui T, Kamiya K, Ishii Y, Tanaka S, Amano S, Oshika T (2002) Intraocular dexamethasone delivery system for corneal transplantation in an animal model. Cornea 21 (2): 200-2
18. De Carvalho, RAP (2002) Pharmacokinetics of a novel intravitreous dexamethasone Biodegradable Drug Delivery System (DEX-BDD). Invest Ophthalmol Vis Sci 43: E-Abstract 3874
19. Spada CS, Lin T, Jackson B, Zhang KM, Orilla W, Escobar M, Tzekov R, Kulkarni A, Wheeler L, Burke J (2005) Posurdex inhibits retinal vasculopathy and neuropathy by Intravitreal Vascular Endothelial Growth Factor (VEGF) in monkeys. Invest Ophthalmol Vis Sci; E-Abstract 3951/B 309
20. Haller JA, Blumenkranz MS, Williams GA, Kuppermann BD and Posurdex Study Group (2003) Treatment of persistent macular edema associated with central and branch retinal vein occlusion with extended delivery of intravitreal dexamethasone. Invest Ophthalmol Vis Sci 44: E-Abstract 4311
21. Williams GA, Blumenkranz MS, Haller JA, Kuppermann BD and Posurdex Study Group (2003) Treatment of Persistent Macular Edema (PME) Associated with uveitis or Irvine-Gass Syndrome (IGS) with an intravitreal Bioerodible Sustained Dexmethasone Release Implant; a prospective controlled multi-center clinical trial. Invest Ophthalmol Vis Sci 44: E-Abstract 4309
22. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA and Posurdex Study Group (2003) An Intravitreous Dexamethasone Bioerodible Drug Delivery System for the treatment of persistent diabetic macular edema. Invest Ophthalmol Vis Sci 44: E-Abstract 4289
23. Haller JA (2003) The Steroid Device: The Oculex Study. Retina Subspecialty Day; pp. 69-71 (presented at the American Academy of Ophthalmology, Nov. 14, 2003, Anaheim, CA)